Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Tissue Repair Advances Wound Trial as US Regulatory Filing Targets 2027

TRP: $0.095 +5.56% · MC: $6M

Tissue Repair reported approximately 112 patients randomised in its ongoing US Phase III chronic-wound trial and is targeting an FDA device application in April 2027, an alternative pathway it says could avoid the full Phase III recruitment plan. TR Pro+ is now available in all three Australian product formats, while the company ended the quarter with approximately $5 million in cash after receiving an R&D tax refund; underlying operating cash outflows were broadly in line with the prior quarter.

Source announcements: 2026-10-29 12:27 to 2026-10-29 12:27 Sydney time
Story updated 2026-10-29 12:32 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments